Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 16k
18 October 2016
E-007815-16
Question for written answer E-007815-16
to the Commission
Rule 130
David Martin (S&D)

 Subject:  Use of primates in neuroscience research
 Answer in writing 

Given the high level of suffering involved and the speculative nature of the benefits, there is concern that primate neuroscience research does not pass the harm-benefit test required by Article 38(2)(d) of Directive 2010/63/EU.

What criteria does the Commission, via DG Research and Innovation, DG Education and Culture and the European Research Council, apply when considering applications for funding for (i) neuroscience research on primates in general, and (ii) neuroscience research on primates which involves head and/or body restraint and/or fluid and/or food restriction in particular?

What consideration does the Commission, via DG Research and Innovation, DG Education and Culture and the European Research Council, give when considering applications for funding to the availability of replacement approaches within Article 4 of the directive, such as non-invasive human studies?

What consideration does the Commission, via DG Research and Innovation, DG Education and Culture and the European Research Council, give when considering applications for funding to the availability of more refined techniques compared with those proposed, with particular reference to restraint and fluid and/or food restriction?

Legal notice